Holen Sie sich die Stockscreener-App
2.83
3.28%
0.09
Handel nachbörslich:
2.82
-0.01
-0.35%
Briacell Therapeutics Corp Aktie (BCTX) Neueste Nachrichten
Why Briacell Therapeutics Corp stock is rising today - Wealth Awesome
Why Briacell Therapeutics Corp stock is plummeting today - Wealth Awesome
BCTXZ SEC FilingsBriacell Therapeutics Corp 10-K, 10-Q, 8-K Forms - Stock Titan
BCTX Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift Shares Amid Revenue AbsenceROE Trend Analysis - newsline.com
BriaCell (NASDAQ: BCTX) ramps cancer trials but flags going concern risk - Stock Titan
BriaCell receives FDA clearance for breast cancer therapy trial - Investing.com
Immunotherapy Innovations: Increasing Survival in Metastatic Breast Cancer - Investing News Network
BriaCell (NASDAQ: BCTX) completes $4.71M best efforts common share sale - Stock Titan
BriaCell Therapeutics Prices $4.71 Million Share Offering at $3.25; ThinkEquity as Placement Agent - TradingView
Beyond the Lab: Top-Tier Clinical Validation in Biotech Investing - Investing News Network
BriaCell Therapeutics Rises After Hours as It Closes a $4.7-Million Share Offering - Moomoo
BriaCell Therapeutics Closes $4.7 Million Share Offering - marketscreener.com
BriaCell Therapeutics Announces Closing of Offering - Investing News Network
BriaCell Therapeutics (BCTX) raises ~$3.94M net in $3.25 share placement - Stock Titan
What Does BriaCell's Latest Offering Mean for Investors - Kavout
BriaCell Presents Positive Clinical Data at ASCO 2026 - Sahm
BriaCell Presenting Final Phase 2, Ongoing Phase 3 Data at ASCO Meeting - Moomoo
BriaCell Therapeutics Prices $4.7 Million Share Offering - Moomoo
BriaCell Down 9.3% as Prices Offering to Raise US$4.7 Million - marketscreener.com
What Does BriaCell's Latest Offering Mean for Shareholders - Kavout
BriaCell Therapeutics Announces Pricing of Offering - Moomoo
BriaCell Prices Public Offering With Shares at $X and Warrants at $Y - geneonline.com
BriaCell Offering Expected to Close June 2 >BCT.T - Moomoo
BriaCell prices $4.7M share offering to fund cancer immunotherapy development - Pluang
Briacell Therapeutics prices 1.45 million common shares at $3.25 per share - marketscreener.com
BriaCell Plans to Use Proceeds for Working Capital Requirements, General Corporate Purposes, Advancement of Business Objectives >BCT.T - Moomoo
Cancer immunotherapy firm BriaCell raises $4.7M for operations - Stock Titan
MSN Money - MSN
BCTXL Warrants Slip Slightly as Consolidation Continues Near $0.95TICK Divergence - newsline.com
(BCT) Risk-Controlled Trading Report (BCT:CA) - Stock Traders Daily
BriaCell Therapeutics Warrants (BCTXL) Slide 3.06% as Momentum Wanes Near $1 ResistanceEMA Signal - newsline.com
BriaCell Therapeutics (BCTX) Surges 6% as Shares Test Key Resistance LevelBlue Chip Entry Points - newsline.com
BriaCell Therapeutics Corp. (BCTX) Stock Price, News, Quote & History - Yahoo Finance
BriaCell (BCTX) Receives Positive Update from Data Safety Monito - GuruFocus
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer - Investing News Network
BCTX - Finviz
BriaCell Says Received Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer - marketscreener.com
Breast cancer trial under FDA Fast Track clears sixth safety review - Stock Titan
BriaCell Therapeutics Q1 2026 Earnings: Narrower-than-Expected EPS Loss Despite No RevenueCrowd Consensus Signals - Newser
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT at ASCO 2026 - Investing News Network
Breast cancer vaccine Bria-IMT shows 16.6-month survival, home-use potential - Stock Titan
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026 - GlobeNewswire
BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026 - GuruFocus
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 - Investing News Network
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7 - Investing News Network
BriaCell develops ovarian cancer immunotherapy candidate - Investing.com India
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):